BioTuesdays
Dyne Logo
Markets

Stifel starts Dyne Therapeutics at buy; PT $29

Stifel initiated coverage of Dyne Therapeutics (NASDAQ:DYN) with a “buy” rating and $29 price target. The stock closed at $18.64 on Oct. 9. “We view Dyne as an emerging leader in the neuromuscular space, and our...

October 12, 2020
Neuronetics Logo
Markets

BTIG ups Neuronetics PT to $10 from $6

BTIG raised its price target for Neuronetics (NASDAQ:STIM) to $10 from $6, citing takeaways from recent virtual investor meetings, which focused on how the company’s new CEO, Keith Sullivan, will be reshaping the...

October 6, 2020
Markets

WB starts Chinook Therapeutics at OP

William Blair initiated coverage of Chinook Therapeutics (NASDAQ:KDNY) with an “outperform” rating. The stock closed at $14.60 on Oct. 5. Chinook recently completed a merger with Aduro Biotech to become a leading...

October 6, 2020
Markets

SVB Leerink starts Immunic at OP, PT $45

SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...

October 2, 2020
Evofem Biosciences Logo
Markets

Stifel starts Evofem Biosciences at buy; PT $5

Stifel initiated coverage of Evofem Biosciences (NASDAQ:EVFM) with a “buy” rating and price target of $5. The stock closed at $2.36 on Oct. 1. The company recently launched a vaginal pH-modulator gel, Phexxi, offering a...

October 2, 2020
Catabasis Pharma
Markets

HCW starts Catabasis Pharma at buy; PT $24

H.C. Wainwright launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $24 price target. The stock closed at $6.19 on Sept. 30. Catabasis is developing edasalonexent, an oral small molecule...

October 1, 2020
Selecta Biosciences
Markets

William Blair cuts Selecta Biosciences to MP

William Blair downgraded Selecta Biosciences (NASDAQ:SELB) to “market perform” after the company and partner, Swedish Orphan Biovitrum, announced top-line data from the Phase 2 COMPARE trial, comparing Selecta’s SEL-212...

October 1, 2020
Markets

AGP starts Trulieve Cannabis at buy; PT $40 (Canadian)

Alliance Global Partners launched coverage of Trulieve Cannabis (CSE:TRUL) with a “buy” rating and $40 (Canadian) price target. The stock was quoted at $23.74 in afternoon trading on Sept. 25. “We view Trulieve as a...

September 25, 2020
Markets

AGP starts Columbia Care at buy; PT $8 (Canadian)

Alliance Global Partners initiated coverage of Columbia Care (CSE:CCHW) with a “buy” rating and price target of $8 (Canadian). The stock was quoted at $4.41 in afternoon trading on Sept. 25. Columbia Care engages in...

September 25, 2020
Markets

Maxim starts Monopar Therapeutics at buy; PT $11

Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...

September 24, 2020
Markets

BTIG starts MediWound at buy; PT $6

BTIG initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $6 price target. The stock closed at $3.58 on Sept. 22. MediWound has developed proteolytic enzyme technology targeting severe burns, chronic...

September 23, 2020
OSE Immunotherapeutics
Markets

HCW ups OSE Immunotherapeutics PT to €10 from €7

H.C. Wainwright raised its price target for OSE Immunotherapeutics (NXT PA:OSE) to €10 from €7, citing strong results in PD-1 refractory non-small cell lung cancer (NSCLC) from the first 100-patient cohort of the Phase...

September 22, 2020
Markets

WB starts Aravive at OP

William Blair launched coverage of Aravive (NASDAQ:ARAV) with an “outperform” rating, saying that an “appreciable market disconnect exists between lead asset AVB-500’s potential to emerge as a differentiated therapeutic...

September 18, 2020
Medicenna Therapeutics
Markets

HCW starts Medicenna Therapeutics at buy; PT $8

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8. Medicenna is an immuno-oncology company developing therapies...

September 10, 2020
Markets

Cowen starts DermTech at OP; PT $20

Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...

September 10, 2020
Motus GI Holdings
Markets

AGP ups Motus GI Holdings PT to $2.60 from $1.65

Alliance Global Partners raised its price target for Motus GI Holdings (NASDAQ:MOTS) to $2.60 from $1.65, “rolling our valuation multiple onto our newly introduced 2022 estimates and utilizing 50 million as our share...

September 9, 2020
Corbus Pharmaceuticals
Markets

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

September 9, 2020
Markets

HCW starts Surface Oncology at buy; PT $11

H.C. Wainwright launched coverage of Surface Oncology (NASDAQ:SURF) with a “buy” rating and $11 price target. The stock closed at $6.40 on Sept. 3. Surface is developing cancer therapies targeting checkpoints that...

September 4, 2020

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.